JP2021518748A - カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 - Google Patents

カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 Download PDF

Info

Publication number
JP2021518748A
JP2021518748A JP2020544204A JP2020544204A JP2021518748A JP 2021518748 A JP2021518748 A JP 2021518748A JP 2020544204 A JP2020544204 A JP 2020544204A JP 2020544204 A JP2020544204 A JP 2020544204A JP 2021518748 A JP2021518748 A JP 2021518748A
Authority
JP
Japan
Prior art keywords
antibody
seq
cgrp
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518748A5 (enExample
Inventor
ジェイ． カルツォーネ，フランク
ジェイ． カルツォーネ，フランク
チャン，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of JP2021518748A publication Critical patent/JP2021518748A/ja
Publication of JP2021518748A5 publication Critical patent/JP2021518748A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544204A 2018-02-23 2019-02-23 カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 Pending JP2021518748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634643P 2018-02-23 2018-02-23
US62/634,643 2018-02-23
PCT/US2019/019319 WO2019165326A1 (en) 2018-02-23 2019-02-23 Calcitonin gene-related peptide (cgrp) antagonist antibodies

Publications (2)

Publication Number Publication Date
JP2021518748A true JP2021518748A (ja) 2021-08-05
JP2021518748A5 JP2021518748A5 (enExample) 2022-02-25

Family

ID=67688456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544204A Pending JP2021518748A (ja) 2018-02-23 2019-02-23 カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体

Country Status (5)

Country Link
US (1) US11629184B2 (enExample)
EP (1) EP3755327A4 (enExample)
JP (1) JP2021518748A (enExample)
CN (1) CN112040949A (enExample)
WO (1) WO2019165326A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
US20260125454A1 (en) * 2022-08-11 2026-05-07 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN117482233A (zh) * 2023-11-01 2024-02-02 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) Cgrp作为治疗靶点在筛选、开发治疗角膜损伤和神经再生药物中的应用
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
WO2026098547A1 (zh) * 2024-11-08 2026-05-15 湖北生物医药产业技术研究院有限公司 一种靶向cgrp的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP2014517699A (ja) * 2011-05-20 2014-07-24 アルダーバイオ・ホールディングズ・エルエルシー 抗ｃｇｒｐ組成物およびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
EP2516470B1 (en) * 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
CN105777907B (zh) * 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
EP2906596B1 (en) * 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
EP3200822B1 (en) * 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP2014517699A (ja) * 2011-05-20 2014-07-24 アルダーバイオ・ホールディングズ・エルエルシー 抗ｃｇｒｐ組成物およびその使用

Also Published As

Publication number Publication date
US20200407433A1 (en) 2020-12-31
WO2019165326A1 (en) 2019-08-29
EP3755327A1 (en) 2020-12-30
EP3755327A4 (en) 2021-11-24
CN112040949A (zh) 2020-12-04
US11629184B2 (en) 2023-04-18

Similar Documents

Publication Publication Date Title
JP7128529B2 (ja) プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
JP2020508655A (ja) 細胞傷害性ｔリンパ球抗原−４（ｃｔｌａ−４）に結合する抗体を使用した癌治療
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
US20250353915A1 (en) Antibodies to galectin-3 and methods of use thereof
US11629184B2 (en) Calcitonin gene-related peptide (CGRP) antagonist antibodies
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7825633B2 (ja) ガレクチン－３に対する抗体及びその使用方法
JP7122758B2 (ja) プログラム死－１（ｐｄ－１）に結合する抗体を使用する免疫療法
CN113906053B (zh) 抗cea抗体及其应用
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN115702003A (zh) 趋化因子受体4(cxcr4)拮抗剂抗体
JP2024500512A (ja) 抗ｂ７－ｈ３抗体およびその使用
CN118047871A (zh) 一种靶向FRα的抗体或其抗原结合片段及其应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN114761042A (zh) Il-38特异性抗体
US12606631B2 (en) Antibodies which bind human endothelin receptor a (ETAR)
JP2021519589A (ja) インターロイキン１７ａ（ｉｌ−１７ａ）に結合する抗体を用いた自己免疫障害及び炎症障害の治療
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231010